Last reviewed · How we verify
tegafur-uracil
tegafur-uracil is a Antimetabolite; 5-fluorouracil prodrug Small molecule drug developed by Yokohama City University. It is currently FDA-approved for Colorectal cancer, Gastric cancer, Breast cancer. Also known as: UFUR, ufur, UFT.
Tegafur-uracil is a combination prodrug that is converted to fluorouracil in the body to inhibit thymidylate synthase and disrupt DNA synthesis in cancer cells.
Tegafur-uracil is a chemotherapy drug combination used to treat various types of cancer, including gastric cancer, colorectal cancer, stomach neoplasm, and hepatoid adenocarcinoma of the stomach. It is a small molecule modality that works as part of a treatment regimen, often in combination with other medications.
At a glance
| Generic name | tegafur-uracil |
|---|---|
| Also known as | UFUR, ufur, UFT |
| Sponsor | Yokohama City University |
| Drug class | Antimetabolite; 5-fluorouracil prodrug |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Tegafur is a prodrug of 5-fluorouracil (5-FU) that undergoes hepatic metabolism to release active 5-FU. Uracil is a competitive inhibitor of dihydrouracil dehydrogenase, which normally degrades 5-FU, thereby prolonging 5-FU exposure and enhancing its cytotoxic effects. The combination allows for oral administration with improved bioavailability compared to intravenous 5-FU.
Approved indications
- Colorectal cancer
- Gastric cancer
- Breast cancer
Common side effects
- Bone marrow suppression (leukopenia, thrombocytopenia)
- Gastrointestinal toxicity (nausea, diarrhea, stomatitis)
- Hand-foot syndrome
- Anemia
Key clinical trials
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) (PHASE2)
- Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer (PHASE3)
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (PHASE3)
- Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma (PHASE2)
- Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer (PHASE2)
- A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (PHASE1)
- Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tegafur-uracil CI brief — competitive landscape report
- tegafur-uracil updates RSS · CI watch RSS
- Yokohama City University portfolio CI
Frequently asked questions about tegafur-uracil
What is tegafur-uracil?
How does tegafur-uracil work?
What is tegafur-uracil used for?
Who makes tegafur-uracil?
Is tegafur-uracil also known as anything else?
What drug class is tegafur-uracil in?
What development phase is tegafur-uracil in?
What are the side effects of tegafur-uracil?
What does tegafur-uracil target?
Related
- Drug class: All Antimetabolite; 5-fluorouracil prodrug drugs
- Target: All drugs targeting Thymidylate synthase
- Manufacturer: Yokohama City University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Colorectal cancer
- Indication: Drugs for Gastric cancer
- Indication: Drugs for Breast cancer
- Also known as: UFUR, ufur, UFT
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing